Aethlon Medical dosed first patient in final cohort of Australia oncology trial

Aethlon Medical announced on August 13, 2026 that it had dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia¹. CEO and CFO James Frakes said early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier¹.

The company reported that observations from the earlier cohorts pointed to reductions in tumor-linked extracellular vesicles and microRNAs tied to cancer progression, along with signs of improved immune function that could be associated with response to immunotherapy, though it cautioned that these observations are preliminary and will be evaluated fully after study completion¹.

Separately, Aethlon said a manuscript on extracellular vesicle characteristics in Long COVID patients was accepted for publication in the International Journal of Molecular Sciences, and that the manuscript demonstrates that the extracellular vesicles isolated from the plasma of individuals with Long COVID bind to the proprietary GNA affinity resin in the Hemopurifier¹.

On the financial side, the company reported cash and cash equivalents of approximately $4.9 million as of June 30, 2026¹. It also disclosed that subsequent to quarter-end, it raised approximately $4.0 million in gross proceeds through a public offering of common stock¹. Based on those resources, the company said it believes its cash resources are sufficient to fund operations for at least the next 12 months¹.

Aethlon added that quarterly operating expenses fell year over year, which it attributed to lower professional fees and reduced general and administrative and preclinical research spending, with operating loss declining in step.